The Corvidia Approach

At Corvidia Therapeutics, we are creating precision therapies by using the science of genomics in new ways. Through random genetic mutation, nature conducts experiments, subtly changing how key proteins work in our bodies and influencing the factors that drive diseases differently in different groups of patients. We study the networks of these genetic variations and how they affect specific diseases in specific patients, allowing us to understand how a personalized drug in complex diseases may behave before we ever begin a clinical trial.  We believe that by leveraging the inner networks of genomics we can develop therapies tailored to patients across a range of complex diseases. Working together, our team of distinguished scientists, experienced drug developers and a successful group of investors are focused on bringing these innovations to patients.

Our Portfolio

We have a portfolio of novel therapeutic candidates, focused primarily on renal disease and cardiovascular disease. Our goal is to utilize our study of genetic variations to ultimately deliver precise treatments to specific patients who presently have an unmet medical need in these diseases.


Our Patient Focus

We believe that no two patients are identical in their treatment needs and there are vast number of patients around the world whose needs are presently unmet. Using our precise approach to study the genetic variations of diseases and the patients they affect, we understand how a personalized drug in these complex diseases may behave before we ever begin a clinical trial. Approximately 2.5 million people worldwide suffer from advanced renal or kidney disease*. The greatest threat to these patients is the risk of cardiovascular events. Inflammation is a key factor that increases the chances of a serious cardiac event in these patients. In addition to an increased risk of heart failure, advanced kidney disease patients who have inflammation often have a significantly decreased quality of life, experiencing anemia, chronic exhaustion, muscle weakness, loss of appetite and depression. Dialysis is the current treatment paradigm for advanced kidney disease. We believe that by applying our understanding of the networks of genetic variation, we can for the first time address the chronic inflammation of advanced kidney disease in a uniquely at-risk population, limiting the systemic effects of this inflammation, thereby improving quality of life while further enhancing current renal care.


Our Future

Among our portfolio of novel therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with Chronic Kidney Disease. Our other preclinical programs are in various stages of development and are focused on cardiovascular diseases.

* Source: U.S. Renal Data System (USRDS)

Management Team

Board of Directors

Sylvie Grégoire – Board Chair

Sylvie Grégoire, has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 3 public companies: Galenica, a Swiss pharmaceutical company, NovoNordisk a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.

MARC DE GARIDEL – CEO, Corvidia Therapeutics

Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA between 2010 and 2016 where he led the company through a significant transformation and spearheaded growth of operations in the United States. Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA. Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.

Graziano Seghezzi – Sofinnova Partners

Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).

Seth Harrison – Apple Tree Partners

Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He is currently also Chairman of Tokai Pharmaceuticals, Chairman of Aileron Therapeutics and Deputy Chairman of Heartware International, all companies he founded. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.

Tyrell Rivers - AstraZeneca

Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s corporate development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing and, at Merck & Company, Inc. where he led the technical support for multiple commercial vaccine franchises, subsequently directing global business initiatives for accessing key technologies in research and development. Dr. Rivers earned his Bachelor of Science degree in chemical engineering from the Massachusetts Institute of Technology and his PhD in chemical engineering from University of Texas at Austin. He earned his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for G1 Therapeutics (GTHX), Viela Bio and Armaron Bio Ltd. He is a board observer for several private companies.


Press release: (Mar 29th 2018)

Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer

Press release: (Jun 14th 2016)

Sylvie Grégoire Appointed as Chair of the Board of Directors

Press release: (Feb 16th 2016)

Corvidia Therapeutics Raises $26M Series A Financing


Seeking motivated, self directed, interested in changing the paradigm of cardiovascular diseases.
For more info contact –